MedTrace Logo

ctDNA for Early Detection of Recurrence in Melanoma

NCT06246227 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 467

Last updated 2026-04-24

No results posted yet for this study

Summary

This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or earlier than current methods, leading to improved management and hopefully prognosis, based on earlier detection.

Conditions

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Danish Cancer Research Foundation

    collaborator OTHER

  • DCCC ctDNA Research Center

    collaborator UNKNOWN

  • CAG in Cancer immunotherapy

    collaborator UNKNOWN

  • Herlev and Gentofte Hospital

    lead OTHER

Principal Investigators

  • Lisbet R Hölmich, MD, DMSc, Clinical Professor · Dept. of Plastic and Reconstructive Surgery, Herlev and Gentofte University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2027-10-06
Completion
2028-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06246227 on ClinicalTrials.gov